I believe "they" are not lining up at the door for the savings, because the savings are becoming less and less as time goes by. If GTCB had been at this point 3-4 years ago, the line would have been long, but significant advances in cell culture expression have big biotech pretty happy with what they already have. I hear the same story from unrelated people involved in research, patent law, and investment funds. The window to generate excitement over the platform, and by this I mean all transgenics, is not as open as it once was.
That said, I still expect good things here.
News 
Market Data 
Discover 
